scholarly journals Exercise training to reduce cardiovascular risk in patients with metabolic syndrome and type 2 diabetes mellitus: How does it work?

2018 ◽  
Vol 26 (7) ◽  
pp. 701-708 ◽  
Author(s):  
Nicolle Kränkel ◽  
Martin Bahls ◽  
Emeline M. Van Craenenbroeck ◽  
Volker Adams ◽  
Luis Serratosa ◽  
...  

Metabolic syndrome (MetS) – a clustering of pathological conditions, including abdominal obesity, hypertension, dyslipidemia and hyperglycaemia – is closely associated with the development of type 2 diabetes mellitus (T2DM) and a high risk of cardiovascular disease. A combination of multigenetic predisposition and lifestyle choices accounts for the varying inter-individual risk to develop MetS and T2DM, as well as for the individual amount of the increase in cardiovascular risk in those patients. A physically active lifestyle can offset about half of the genetically mediated cardiovascular risk. Yet, the extent to which standardized exercise programmes can reduce cardiovascular risk differs between patients. Exercise parameters, such as frequency, intensity, type and duration or number of repetitions, differentially target metabolic function, vascular health and physical fitness. In addition, exercise-induced molecular mechanisms are modulated by other patient-specific variables, such as age, diet and medication. This review discusses the molecular and cellular mechanisms underlying the effects of exercise training on cardiovascular risk specifically in patients with MetS and T2DM.

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1412
Author(s):  
Chong-Hyun Shin ◽  
Ki-Hye Kim ◽  
Subbiah Jeeva ◽  
Sang-Moo Kang

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gave rise to the coronavirus disease 2019 (COVID-19) pandemic. A strong correlation has been demonstrated between worse COVID-19 outcomes, aging, and metabolic syndrome (MetS), which is primarily derived from obesity-induced systemic chronic low-grade inflammation with numerous complications, including type 2 diabetes mellitus (T2DM). The majority of COVID-19 deaths occurs in people over the age of 65. Individuals with MetS are inclined to manifest adverse disease consequences and mortality from COVID-19. In this review, we examine the prevalence and molecular mechanisms underlying enhanced risk of COVID-19 in elderly people and individuals with MetS. Subsequently, we discuss current progresses in treating COVID-19, including the development of new COVID-19 vaccines and antivirals, towards goals to elaborate prophylactic and therapeutic treatment options in this vulnerable population.


Metabolism ◽  
2010 ◽  
Vol 59 (4) ◽  
pp. 599-607 ◽  
Author(s):  
Nikolaos P.E. Kadoglou ◽  
Fotios Iliadis ◽  
Nikolaos Sailer ◽  
Zoi Athanasiadou ◽  
Ioulia Vitta ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document